Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

The experimental drug combines GLP-1 and amylin hormones, offering potential advances in obesity treatment.

Novo Nordisk reported early-stage trial results for its experimental obesity drug, amycretin, showing up to 22% weight loss over 36 weeks at the highest dosage.
The drug combines GLP-1 and amylin receptor agonists, targeting hunger and appetite regulation more effectively than existing treatments like Wegovy and Ozempic.
The trial involved 125 participants and demonstrated consistent safety, with most side effects being mild to moderate gastrointestinal issues.
Amycretin's promising results come as Novo Nordisk faces increasing competition in the obesity drug market, particularly from Eli Lilly's Zepbound and Mounjaro.
Novo Nordisk plans further clinical trials to confirm these findings and potentially position amycretin as a next-generation obesity treatment.